2016 Hematological Malignancies

Advanced stage HL Summary

• HL became curable with the introduction of multi-agent chemo • ABVD associated with 65-70% PFS and 75-80% OS @5yrs • B.esc gave 15-20% better PFS and 10-15% better OS than ABVD • Treatment-related mortality and 2 nd npl of BEACOPP similar to ABVD; more hematotox and infertility • 6xB.esc: tumour control 89%, OS 95%; PET-guided RT (HD15) • B.esc not to be used in pts >40 yrs and poor performance • Ongoing trials evaluate PET-guided strategies and combining BV with ABVD (enhance efficacy) BEACOPP (reduce toxicity)